Author-year/country | Patients (N) | Disease | Agreement with TST | RoB |
Ruan et al17 2016/NA* | 1940 | AIIRD | 72% (QTF) 75% (T-Spot) | High quality |
Pyo et al44 2018/NA* | 5224 | AIIRD | 73% (QTF) 75% (T-Spot) | Medium quality |
Escalante et al34 2015/USA | 101 | AIIRD | 81% (T-Spot) | 7 |
Tang et al46 2020/Hong Kong | 217 | AIIRD | 74.4% (QTF) | 6 |
Wu et al48 2019/China | 173 | BD | 0.391† (T-Spot) | 6 |
Klein et al18 2013/Czech | 305 | AIIRD | 66% (QTF) | 6 |
Vassilopoulos et al55 2011/Greece | 155 | AIIRD | 64% (QTF) 71% (T-Spot) | 6 |
Park et al 43 2009/South Korea | 86 | AIIRD | 68.6% (IGRA) | 6 |
Vassilopoulos et al15 2008/Greece | 70 | AIIRD | 72.8% (T-Spot) | 6 |
Cho et al33 2016/South Korea | 136/66 | SLE/RA | 84.6%/78.8% (QTF) | 5 |
Kim et al39 2013/South Korea | 724 | IA | 0.285† (QTF) | 5 |
Lee et al40 2013/South Korea | 64 | RA | 75% (QTF) | 5 |
Minguez et al41 2012/Spain | 53 | IA | 77.3% (QTF) | 5 |
Scrivo et al45 2013/Italy | 102 | AIIRD | 88% (QTF) | 5 |
Paluch-oles et al42 2013/Poland | 90 | IA | 82% (QTF) | 5 |
Maeda et al14 2011/Japan | 97 | RA | 50.5% (QTF) | 5 |
Inanc et al38 2009/Turkey | 140 | IA | 61% (QTF) | 4 |
Girlanda et al35 2010/Italy | 69 | AIIRD | 0.341† (T-Spot) | 4 |
Gogus et al36 2010/Tureky | 45 | IA | 0.188† (QTF) | 4 |
Xie et al49 2011/China | 58 | AIIRD | 88.2% (T-Spot) | 4 |
Hanta et al37 2012/Turkey | 90 | IA | 0.12† (QTF) | 4 |
So et al50 2017/Hong Kong | 38 | RA | 73.7% (QTF) | 4 |
Author-year/country | Patients (N) | Disease | Agreement among IGRA | RoB |
Vassilopoulos et al55 2011/Greece | 155 | AIIRD | 81% | 6 |
Martin et al53 2010/Ireland | 150 | AIIRD | 98% | 6 |
Iwagaitsu et al52 2016/Japan | 68 | RA | 0.68† | 4 |
Melath et al54 2014/UK | 76 | AIIRD | 91% | 4 |
*Meta-analysis.
†Only k coefficient is available.
AIIRD, autoimmune inflammatory rheumatic diseases; BD, Bechet’s disease; IA, inflammatory arthritis; IGRA, interferon gamma release assay; IMID, immune mediated inflammatory disease; N, number; NA, not applicable; QTF, quantiferon; RA, rheumatoid arthritis; RoB, risk of bias; SLE, systemic lupus erythematosus; TST, tuberculin skin test.